Association of antinuclear antibody seropositivity with inhaled environmental exposures in patients with interstitial lung disease.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
12
04
2021
accepted:
02
08
2021
entrez:
11
11
2021
pubmed:
12
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Interstitial lung diseases (ILDs) are diffuse parenchymal lung disorders that cause substantial morbidity and mortality. In patients with ILD, elevated antinuclear antibody (ANA) titres may be a sign of an autoimmune process. Inhalational exposures contribute to ILD pathogenesis and affect prognosis and may trigger autoimmune disease. The association of inhalational exposures with ANA seropositivity in ILD patients is unknown. This was a retrospective cohort study of adult ILD patients from five centres in the United States. Exposures to tobacco, inhaled organic antigens and inhaled inorganic particles were extracted from medical records. A multivariable logistic regression model was used to analyse the effects of confounders including age, ILD diagnosis, gender and exposure type on ANA seropositivity. Among 1265 patients with ILD, there were more ANA-seropositive (58.6%, n=741) than ANA-seronegative patients (41.4%, n=524). ANA-seropositive patients had lower total lung capacity (69% Patients with ILD and inhalational exposure had significantly higher prevalence of ANA-seropositivity than those without reported exposures across ILD diagnoses. Environmental and occupational exposures should be systematically reviewed in patients with ILD, particularly those with ANA-seropositivity.
Sections du résumé
BACKGROUND
BACKGROUND
Interstitial lung diseases (ILDs) are diffuse parenchymal lung disorders that cause substantial morbidity and mortality. In patients with ILD, elevated antinuclear antibody (ANA) titres may be a sign of an autoimmune process. Inhalational exposures contribute to ILD pathogenesis and affect prognosis and may trigger autoimmune disease. The association of inhalational exposures with ANA seropositivity in ILD patients is unknown.
METHODS
METHODS
This was a retrospective cohort study of adult ILD patients from five centres in the United States. Exposures to tobacco, inhaled organic antigens and inhaled inorganic particles were extracted from medical records. A multivariable logistic regression model was used to analyse the effects of confounders including age, ILD diagnosis, gender and exposure type on ANA seropositivity.
RESULTS
RESULTS
Among 1265 patients with ILD, there were more ANA-seropositive (58.6%, n=741) than ANA-seronegative patients (41.4%, n=524). ANA-seropositive patients had lower total lung capacity (69%
CONCLUSION
CONCLUSIONS
Patients with ILD and inhalational exposure had significantly higher prevalence of ANA-seropositivity than those without reported exposures across ILD diagnoses. Environmental and occupational exposures should be systematically reviewed in patients with ILD, particularly those with ANA-seropositivity.
Identifiants
pubmed: 34761002
doi: 10.1183/23120541.00254-2021
pii: 00254-2021
pmc: PMC8573239
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL146942
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130796
Pays : United States
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: K. Biblowitz has nothing to disclose. Conflict of interest: C. Lee has nothing to disclose. Conflict of interest: D. Zhu has nothing to disclose. Conflict of interest: I. Noth has nothing to disclose. Conflict of interest: R. Vij has nothing to disclose. Conflict of interest: M.E. Strek has received institutional support to conduct interstitial lung disease clinical trials for Boehringer Ingelheim and Galapagos, fees for clinical trial adjudication committee service from Fibrogen, and editorial support from Boehringer Ingelheim. Conflict of interest: S.K. Bellam has received speaking and advisory board fees from Genentech. Conflict of interest: A. Adegunsoye has received speaking and advisory board fees from Genentech and Boehringer Ingelheim, and is supported by a career development award from the National Heart, Lung, and Blood Institute (NHLBI K23HL146942).
Références
Int J Mol Sci. 2014 Dec 03;15(12):22279-95
pubmed: 25479074
Autoimmun Rev. 2016 Feb;15(2):162-6
pubmed: 26524640
Arthritis Res Ther. 2014 Mar 05;16(2):R61
pubmed: 24594022
Eur Respir J. 2001 Jan;17(1):122-32
pubmed: 11307741
Am J Respir Crit Care Med. 2020 Feb 1;201(3):378-380
pubmed: 31597045
Eur Respir J. 2018 Jun 14;51(6):
pubmed: 29724923
Rheumatol Int. 2016 May;36(5):697-702
pubmed: 26759224
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Arch Pathol Lab Med. 2000 Jan;124(1):71-81
pubmed: 10629135
Arthritis Care Res (Hoboken). 2018 Apr;70(4):499-509
pubmed: 28795508
Respir Med. 2016 May;114:53-60
pubmed: 27109811
Chest. 2009 Nov;136(5):1397-1405
pubmed: 19892679
Environ Health Perspect. 2005 Jan;113(1):25-30
pubmed: 15626643
Chest. 2011 Nov;140(5):1292-1299
pubmed: 21565966
Gerodontology. 2017 Mar;34(1):86-89
pubmed: 27173106
BMJ. 2016 Feb 24;352:h6819
pubmed: 26912511
Arthritis Rheum. 1997 Sep;40(9):1601-11
pubmed: 9324014
Int J Hyg Environ Health. 2012 Nov;215(6):562-9
pubmed: 22153879
Environ Health Perspect. 2011 Jan;119(1):45-9
pubmed: 20870568
Ann Rheum Dis. 2010 Jan;69(1):70-81
pubmed: 19174392
Respir Med. 2013 Feb;107(2):249-55
pubmed: 23186614
Chest. 2021 Jul;160(1):209-218
pubmed: 33621598
N Engl J Med. 2018 May 10;378(19):1811-1823
pubmed: 29742380
Eur Respir J. 2015 Oct;46(4):976-87
pubmed: 26160873
Mol Immunol. 2005 May;42(7):833-8
pubmed: 15829271
Front Med (Lausanne). 2017 Oct 16;4:170
pubmed: 29085824
Clin Rheumatol. 2003 Oct;22(4-5):365-6
pubmed: 14577001
Eur Respir J. 2017 Aug 3;50(2):
pubmed: 28775045
Am J Clin Pathol. 2011 May;135(5):678-84
pubmed: 21502422
Clin Diagn Lab Immunol. 1997 Mar;4(2):185-8
pubmed: 9067653